[go: up one dir, main page]

AR126517A1 - Método para producir un derivado de aril amida - Google Patents

Método para producir un derivado de aril amida

Info

Publication number
AR126517A1
AR126517A1 ARP220101914A ARP220101914A AR126517A1 AR 126517 A1 AR126517 A1 AR 126517A1 AR P220101914 A ARP220101914 A AR P220101914A AR P220101914 A ARP220101914 A AR P220101914A AR 126517 A1 AR126517 A1 AR 126517A1
Authority
AR
Argentina
Prior art keywords
methyl
amide derivative
aryl amide
fluoropyridin
amino
Prior art date
Application number
ARP220101914A
Other languages
English (en)
Inventor
Kazuaki KUWATA
Hidehisa SOMEYA
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of AR126517A1 publication Critical patent/AR126517A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/22—Organic complexes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24—Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B61/00—Other general methods
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/66—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona, por ejemplo, un método para elaborar 2-(4-ciclopropil-2-fluoroanilino)-3,4-difluoro-5-[[3-fluoro-2-(metilsulfamoilamino)piridin-4-il]metil]benzamida o una sal farmacéuticamente aceptable del mismo, o un solvato farmacéuticamente aceptable del compuesto o sal, el método comprende hacer reaccionar (2-amino-3-fluoropiridin-4-il)metanol con metil cloroformiato y N,N-dimetilaminopiridina en acetonitrilo para obtener (2-amino-3-fluoropiridin-4-il)metil metil carbonato. De acuerdo con la presente invención, se proporciona un método para elaborar un derivado de aril amida específico que ejerce una actividad estabilizadora del complejo RAF / MEK y/o actividad inhibidora de MEK y que resulta de utilidad para el tratamiento o la prevención de un trastorno celular proliferativo, particularmente un cáncer, el método permite que el derivado de aril amida sea producido con un menor número de etapas.
ARP220101914A 2021-07-21 2022-07-20 Método para producir un derivado de aril amida AR126517A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2021120977 2021-07-21

Publications (1)

Publication Number Publication Date
AR126517A1 true AR126517A1 (es) 2023-10-18

Family

ID=84980009

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220101914A AR126517A1 (es) 2021-07-21 2022-07-20 Método para producir un derivado de aril amida

Country Status (12)

Country Link
US (1) US20240327355A1 (es)
EP (1) EP4375273A4 (es)
JP (2) JP7268255B1 (es)
KR (1) KR102671612B1 (es)
CN (1) CN117677607A (es)
AR (1) AR126517A1 (es)
AU (1) AU2022312992A1 (es)
CA (1) CA3226827A1 (es)
IL (1) IL310123A (es)
MX (1) MX2024000908A (es)
TW (1) TW202321198A (es)
WO (1) WO2023003014A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025007811A1 (zh) * 2023-07-06 2025-01-09 成都华健未来科技有限公司 一类芳香酰胺类衍生物及其用途
WO2025146040A1 (zh) * 2024-01-01 2025-07-10 华健未来（成都）科技股份有限公司 芳香酰肼类衍生物及其医药用途
CN118604164B (zh) * 2024-05-15 2025-06-06 石家庄四药有限公司 一种非奈利酮中间体中杂质的检测方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4931419B2 (ja) * 2003-09-19 2012-05-16 中外製薬株式会社 新規４−フェニルアミノ−ベンズアルドオキシム誘導体並びにそのｍｅｋ阻害剤としての使用
TWI361066B (en) 2004-07-26 2012-04-01 Chugai Pharmaceutical Co Ltd 5-substituted-2-phenylamino benzamides as mek inhibitors
AR059339A1 (es) 2006-02-09 2008-03-26 Chugai Pharmaceutical Co Ltd Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene
JP2016034900A (ja) * 2012-11-26 2016-03-17 中外製薬株式会社 ５−置換−２−フェニルアミノ−ベンズアミド類の製造方法
AR121078A1 (es) * 2020-01-22 2022-04-13 Chugai Pharmaceutical Co Ltd Derivados de arilamida con actividad antitumoral
WO2022019329A1 (ja) * 2020-07-22 2022-01-27 中外製薬株式会社 アリールアミド誘導体を含む組成物
WO2022018875A1 (ja) * 2020-07-22 2022-01-27 中外製薬株式会社 アリールアミド誘導体を含む細胞増殖性疾患の治療又は予防用医薬組成物

Also Published As

Publication number Publication date
AU2022312992A1 (en) 2024-02-29
KR20230152797A (ko) 2023-11-03
WO2023003014A1 (ja) 2023-01-26
JP7268255B1 (ja) 2023-05-02
US20240327355A1 (en) 2024-10-03
MX2024000908A (es) 2024-02-07
KR102671612B1 (ko) 2024-05-31
CA3226827A1 (en) 2023-01-26
CN117677607A (zh) 2024-03-08
JP2023084138A (ja) 2023-06-16
EP4375273A4 (en) 2025-05-21
TW202321198A (zh) 2023-06-01
EP4375273A1 (en) 2024-05-29
JPWO2023003014A1 (es) 2023-01-26
IL310123A (en) 2024-03-01

Similar Documents

Publication Publication Date Title
AR126517A1 (es) Método para producir un derivado de aril amida
CL2023000199A1 (es) Composición que contiene un derivado de arilamida
US11440893B2 (en) Prodrugs of riluzole and their method of use
CR20220390A (es) Derivados de arilamida con actividad antitumoral
CL2021001973A1 (es) Compuesto heterocíclico y su uso.
AR114631A1 (es) Métodos e intermedios para preparar compuestos de piridina
CU24735B1 (es) Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2
AR117101A1 (es) Síntesis mejorada del intermedio clave del compuesto inhibidor de g12c de kras
CO2022015927A2 (es) Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2 y métodos de uso
MX2024007834A (es) Panel de parche de alta densidad con estuches modulares.
AR115015A1 (es) Derivados de azaespiro piperazina
CL2021002234A1 (es) Inhibidor de la interacción proteína-proteína wdr5 basado en anilina, método para preparar el mismo y uso del mismo
CA2458009A1 (en) Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment
MX2021001116A (es) Metodos para purificar sulfato de isavuconazonio.
BR112021025181A2 (pt) Método para biotransformação de tricotecenos
CL2021002316A1 (es) Síntesis de 4-amino-5-metil-1h-piridin-2(1h)-on (compuesto intermediario para la síntesis del antagonista mr finerenona) a partir de 2-cloro-5-metil-4-nitro-piridina-1-oxido usando el compuesto intermediario 2-cloro-5-metil-4-piridinamina
CO2022015976A2 (es) Síntesis de intermedios de vinil ciclobutilo
BR112015019034A2 (pt) processos para fermentar substrato contendo co e para evitar a inibição de co durante a fermentação de substrato contendo co
MX2019000138A (es) Procesos novedosos para preparacion de estimuladores de guanilato ciclasa soluble.
BR112023018246A2 (pt) Formas de sal e sólidas de um inibidor de cinase
BR112020020549A8 (pt) Novo processo para síntese de um composto fenoxi diaminopirimidina
AR057961A1 (es) Derivados de pirrolopirimidinas con actividad inhibitoria de receptor de tirosina quinasa. composiciones farmaceuticas.
MX2022006910A (es) Tratamiento para la leucemia mieloide aguda o para el síndrome mielodisplásico.
MX2023013128A (es) Cristales de sulfato de compuesto agonista del receptor de melanocortina, y metodo para producir los mismos.
ES466968A1 (es) Procedimiento para la preparacion de pirazolo -oxazepinas y de pirazolo-tiazepinas.

Legal Events

Date Code Title Description
FB Suspension of granting procedure